Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
11
×
Tags
clinical trials
11
×
life sciences
national blog main
11
×
biotech
boston blog main
boston top stories
fda
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
seattle blog main
alnylam pharmaceuticals
boston
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
europe top stories
investing
novartis
raleigh-durham top stories
roche
seattle top stories
texas blog main
texas top stories
type 1 diabetes
venture capital
wisconsin blog main
wisconsin top stories
akcea therapeutics
boston university
What
patients
11
×
fda
drug
approved
disease
friday
help
medicine
new
ago
alnylam
bio
daily
diabetes
gets
market
million
nod
parkinson’s
roundup
sets
startup
therapy
time
type
acorda
add
advantages
akcea
amyloidosis
analytics
approval
approve
aren’t
atrophy
attr
available
awaits
bar
battle
Language
unset
Current search:
photo
×
" national blog main "
×
" clinical trials "
×
patients
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision